Year,Observation status,Nature of data points,Observation-level footnotes,Unit multiplier,Source details,Frequency of observation,Reporting type,SERIES,Reference area,Age,UNIT_MEASURE,Value
2015,Normal value,Not Available,Children 12-23 months fully immunized,Units,"DHS, NISR",Annual,National,Children 12-23 months fully immunized,Rwanda,12 to 23 Months old,Percent,93
2018,Normal value,Not Available,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Units,RBC,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1],Rwanda,,Percent,97
2019,Normal value,Not Available,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Units,RBC,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1],Rwanda,,Percent,98
2018,Normal value,Not Available,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Units,RBC,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1],Rwanda,,Percent,92
2019,Normal value,Not Available,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Units,RBC,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1],Rwanda,,Percent,92
2018,Normal value,Not Available,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Units,RBC,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1],Rwanda,,Percent,97
2019,Normal value,Not Available,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Units,RBC,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1],Rwanda,,Percent,98
